King Luther Capital Management Corp Buys 184,290 Shares of Cellebrite DI Ltd. $CLBT

King Luther Capital Management Corp lifted its stake in Cellebrite DI Ltd. (NASDAQ:CLBT – Free Report) by 28.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 829,337 shares of the company’s stock after purchasing an additional 184,290 shares during the period. King Luther Capital Management Corp owned 0.33% of Cellebrite DI worth $9,338,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of CLBT. Nine Ten Capital Management LLC increased its position in shares of Cellebrite DI by 19.8% during the second quarter. Nine Ten Capital Management LLC now owns 4,126,808 shares of the company’s stock valued at $60,251,000 after buying an additional 682,933 shares during the period. Wellington Management Group LLP boosted its position in Cellebrite DI by 93.7% during the 2nd quarter. Wellington Management Group LLP now owns 3,049,904 shares of the company’s stock valued at $44,529,000 after acquiring an additional 1,475,579 shares in the last quarter. Renaissance Technologies LLC grew its holdings in shares of Cellebrite DI by 14.7% during the 1st quarter. Renaissance Technologies LLC now owns 2,860,639 shares of the company’s stock worth $39,420,000 after acquiring an additional 365,700 shares during the period. Principal Financial Group Inc. grew its holdings in shares of Cellebrite DI by 33.9% during the 1st quarter. Principal Financial Group Inc. now owns 2,156,166 shares of the company’s stock worth $29,712,000 after acquiring an additional 545,334 shares during the period. Finally, Weiss Asset Management LP grew its holdings in shares of Cellebrite DI by 3,485.3% during the 1st quarter. Weiss Asset Management LP now owns 1,899,841 shares of the company’s stock worth $26,180,000 after acquiring an additional 1,846,851 shares during the period. 45.88% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

CLBT has been the subject of several research reports. DA Davidson reissued a “buy” rating and issued a $15.00 target price on shares of Cellebrite DI in a research report on Tuesday, September 15th. Lake Street Capital dropped their price target on Cellebrite DI from $21.00 to $15.00 and set a “buy” rating on the stock in a research report on Friday, August 14th. Needham & Company LLC dropped their price target on Cellebrite DI from $15.00 to $12.50 and set a “buy” rating on the stock in a research report on Friday, August 14th. Weiss Ratings cut Cellebrite DI from a “sell (d+)” rating to a “sell (d)” rating in a research note on Thursday, August 27th. Finally, JPMorgan Chase & Co. decreased their price objective on Cellebrite DI from $20.00 to $16.00 and set an “overweight” rating for the company in a report on Friday, August 14th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $14.62.

Check Out Our Latest Analysis on CLBT

Cellebrite DI Stock Performance

CLBT stock opened at $10.89 on Friday. The firm has a 50 day moving average price of $11.61 and a 200-day moving average price of $13.24. Cellebrite DI Ltd. has a 52-week low of $9.58 and a 52-week high of $19.98. The firm has a market capitalization of $2.72 billion, a price-to-earnings ratio of 49.50, a PEG ratio of 1.95 and a beta of 1.06.

Cellebrite DI (NASDAQ:CLBT – Get Free Report) last posted its quarterly earnings data on Thursday, November 12th. The company reported $0.17 earnings per share for the quarter, beating analysts’ consensus estimates of $0.09 by $0.08. The company had revenue of $149.02 million during the quarter, compared to analyst estimates of $145.83 million. Cellebrite DI had a return on equity of 15.58% and a net margin of 11.43%. As a group, sell-side analysts forecast that Cellebrite DI Ltd. will post 0.37 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, insider Thomas Hogan sold 25,299 shares of the stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $11.29, for a total value of $285,625.71. Following the sale, the insider directly owned 765,249 shares of the company’s stock, valued at approximately $8,639,661.21. This represents a 3.20% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CMO David Gee sold 4,323 shares of the firm’s stock in a transaction on Monday, August 24th. The shares were sold at an average price of $11.36, for a total value of $49,109.28. Following the transaction, the chief marketing officer owned 135,281 shares of the company’s stock, valued at $1,536,792.16. The trade was a 3.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 56,909 shares of company stock valued at $641,890. 5.70% of the stock is owned by insiders.

Trending Headlines about Cellebrite DI

These are some of the CLBT headlines that stood out recently:

  • Positive Sentiment: Operating indicators were solid: annual recurring revenue grew 20%, trailing-12-month free-cash-flow margin was 31%, and adjusted EBITDA was $53.6 million, a 36% margin. Cellebrite third-quarter results
  • Neutral Sentiment: Full-year 2026 revenue guidance of $553 million–$558 million includes the $556.8 million consensus estimate, suggesting the annual outlook was broadly on target. Cellebrite third-quarter results
  • Negative Sentiment: Fourth-quarter revenue guidance of $145 million–$150 million was below the $151.6 million consensus estimate. The softer near-term outlook likely weighed on shares despite the quarterly revenue beat. Cellebrite third-quarter results

Cellebrite DI Company Profile

(Free Report)

Cellebrite DI Ltd. develops digital intelligence software and services that help organizations access, collect, preserve and analyze digital evidence. Its tools are used to investigate information from mobile devices, computers, cloud sources and other digital systems. The company’s offerings include its UFED platform for extracting data from digital devices, Physical Analyzer for examining and interpreting evidence, and analytics and case-management tools such as Pathfinder and Guardian. Customers include law enforcement, public safety, intelligence and defense agencies, as well as organizations in the private sector.

Recommended Stories

Institutional Ownership by Quarter for Cellebrite DI (NASDAQ:CLBT)

Receive News & Ratings for Cellebrite DI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellebrite DI and related companies with MarketBeat.com's FREE daily email newsletter.